

Anacor Pharmaceuticals, Inc.
Form SC 13D/A
February 13, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

ANACOR PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, \$0.001 Par Value

(Title of Class of Securities)

032420 101

(CUSIP Number)

Victoria A. Whyte

GlaxoSmithKline plc

980 Great West Road

Brentford, Middlesex TW8 9GS

Telephone: +44 (0)208 047 5000

Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

October 30, 2014

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 032420

101
13D/A2
of 7

SCHEDULE
Page 2

1. Names of Reporting Persons.

GlaxoSmithKline plc

2. Check the Appropriate Box if a Member of a Group

(a)
(b)

3. SEC Use Only
4. Source of Funds

WC

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization

England and Wales

7. Sole Voting Power

2,771,374

8. Shared Voting Power

Number of Shares
Beneficially
Owned by
Each Reporting
Person With:

-0-

9. Sole Dispositive Power

2,771,374

10. Shared Dispositive Power

-0-

11. Aggregate Amount Beneficially Owned by Each Reporting Person

2,771,374 (1)

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares

13. Percent of Class Represented by Amount in Row (11)

6.5% (2)

14. Type of Reporting Person

CO

Footnotes:

(1) Shares of Common Stock held of record by GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of the Reporting Person, issued as of November 30, 2010.

(2) Based on 42,897,186 shares of Common Stock as of October 30, 2014.

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 3

ITEM 1. SECURITY AND ISSUER

This Amendment No. 2 to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on December 10, 2010 (as amended by Amendment No. 1 filed on March 1, 2013, the “Schedule 13D” and as amended by this Amendment No. 2, the “Statement”), with respect to the shares of common stock, par value \$0.001 per share (the “Common Stock”), of Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive offices are located at 1020 East Meadow Circle, Palo Alto, CA 94303-4230. Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Schedule 13D.

ITEM 2. IDENTITY AND BACKGROUND

The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 as attached to Amendment No. 1 in its entirety, and replacing it with Schedule 1 attached hereto.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

The response set forth in Item 5 of the Schedule 13D is hereby amended by deleting the previous response in its entirety and

replacing it with the following:

(a) GlaxoSmithKline plc beneficially owns 2,771,374 shares of Common Stock, issued as of November 30, 2010, which represents 6.5% of the 42,897,186 shares of Common Stock outstanding as of October 30, 2014.

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 4

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2015

GLAXOSMITHKLINE PLC

/s/ Victoria A. Whyte

By: Victoria A. Whyte

Title: Company Secretary

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 5

Schedule I

Name	Business Address	Principal Occupation or Employment	Citizenship
Board of Directors			
Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Executive Officer	British
Simon Dingemans	980 Great West Road Brentford Middlesex, England TW8 9GS 709 Swedeland Road	Executive Director and Chief Financial Officer	British
Dr. Moncef Slaoui	King of Prussia Pennsylvania	Executive Director and Chairman Global Vaccines	Moroccan, Belgian & US
Sir Christopher Gent	19406 980 Great West Road Brentford Middlesex, England TW8 9GS	Chairman and Company Director	British
Sir Philip Hampton	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British
Professor Sir Roy Anderson	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British
Dr. Stephanie Burns	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Stacey Cartwright	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British

Edgar Filing: Anacor Pharmaceuticals, Inc. - Form SC 13D/A

Judy Lewent	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	US
Sir Deryck Maughan	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director	British

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 6

Dr. Daniel Podolsky	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director US
Tom de Swaan	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director Dutch
Lynn Elsenhans	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director US
Jing Ulrich	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director US
Hans Wijers	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director Dutch
Urs Rohner	980 Great West Road Brentford Middlesex, England TW8 9GS	Company Director Swiss

Corporate Executive Team

Sir Andrew Witty	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Executive Officer	British
Simon Dingemans	980 Great West Road Brentford Middlesex, England TW8 9GS	Executive Director and Chief Financial Officer	British
Dr. Moncef Slaoui	709 Swedeland Road		

King of Prussia

Executive Director
Chairman Global Vaccines

Moroccan,
Belgian & US

Pennsylvania

19406

CUSIP No. 032420
101
13D/A2
of 7

SCHEDULE
Page 7

Deirdre Connelly	5 Crescent Drive, Philadelphia, PA 19112	President, North America Pharmaceuticals	US
Nick Hirons	980 Great West Road Brentford Middlesex TW8 9GS	Senior Vice President, Global Ethics and Compliance	British
Abbas Hussain	150 Beach Road 22-00 Gateway West 189720 Singapore Five Moore Drive PO Box 13398	President, Global Pharmaceuticals	British
William Louv	Research Triangle Park North Carolina 27709	Senior Vice President, Core Business Services	US
David Redfern	980 Great West Road Brentford Middlesex, England TW8 9GS	Chief Strategy Officer	British
Claire Thomas	980 Great West Road	Senior Vice President, Human Resources	British

	Brentford Middlesex, England TW8 9GS 980 Great West Road	Senior Vice President, Communications and Government Affairs	British
Philip Thomson	Brentford Middlesex, England TW8 9GS 5 Crescent Drive		
Daniel Troy	Philadelphia, PA 19112 980 Great West Road	Senior Vice President & General Counsel	US
Dr. Patrick Vallance	Brentford Middlesex, England TW8 9GS 980 Great West Road	President, Pharmaceuticals R&D	British
Emma Walmsley	Brentford Middlesex, England TW8 9GS 980 Great West Road	President, Consumer Healthcare	British
Roger Connor	Brentford Middlesex, England TW8 9GS	President, Global Manufacturing & Supply	Irish